# Ivermectin in Adults With Severe COVID-19.

> **NCT04602507** · PHASE2 · TERMINATED · sponsor: **CES University** · enrollment: 75 (actual)

## Conditions studied

- Covid19
- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Ivermectin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04602507
- **Lead sponsor:** CES University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-10
- **Primary completion:** 2021-12-09
- **Final completion:** 2021-12-09
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Lack of severe COVID-19 cases in the place of study
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602507, "Ivermectin in Adults With Severe COVID-19.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04602507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*